Head-to-head evidence
ARO-HSD vs AZD7503
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) mRNA · full MASH / NASH pipeline
ARO-HSD
Developed by Arrowhead Pharmaceuticals
NCT04202354 · Phase 1/2 · completed
This is a small early-phase dose-escalation study: only the healthy-volunteer cohorts were randomized, quadruple-blinded, and placebo-controlled (4 participants per ARO-HSD dose vs 16 pooled placebo), while the suspected-NASH cohorts were open-label with no comparator (6 per dose). The primary endpoint was a safety endpoint — the number of treatment-related adverse events — reported as descriptive counts with no statistical analysis, and the secondary endpoints were pharmacokinetic measurements. With a total of 50 participants and no efficacy endpoint (no histology, imaging, or clinical outcome in NASH), the trial is far too small and early-phase to provide evidence of clinical benefit.
AZD7503
Developed by AstraZeneca
NCT05560607 · Phase 1 · completed
This was an unblinded, single-arm study with no randomization or comparator group, so any change observed cannot be separated from natural variation or a placebo-like effect.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ARO-HSD's landscape · AZD7503's landscape